Finance

2020 Financial Results

• €3,188 million in full-year 2020 sales, up 19.7% like-for-like
   
• Robust sales performance in the fourth quarter, with organic growth of 20.5 % led by sales of molecular biology reagents
   
• Contributive operating income before non-recurring items up nearly 58 % to €613 million, or 19.6 % of sales for the year
   
• Strong cash flow resulting in a financial debt free position at year-end
   
• 2021 guidance:
   
  
  • In a persistently uncertain business environment, sales are expected to increase by between 5 % and 8 % at constant exchange rates and scope of consolidation in 2021. Growth in the first half of 2021 should remain steady, on a par with the trend of Q4 2020.
     
  • 2021 Contributive operating income before non-recurring items should be in line with 2020, at current exchange rates.